Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term teduglutide study in parenteral nutrition-dependent short bowel syndrome after CL0600-004
2004-000439-27Phase 3Completed
- Sponsor
- NPS Pharmaceuticals
- Start
- Apr 2005
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of teduglutide in short bowel syndrome (SBS), sponsored by NPS Pharmaceuticals. Primary endpoints: Reduction in parenteral nutrition volume, Plasma citrulline levels and 2 more. Started Apr 2005; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2004-000439-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000439-27.